Provided by Tiger Trade Technology Pte. Ltd.

Recursion Pharmaceuticals, Inc.

4.27
-0.3600-7.78%
Post-market: 4.270.00000.00%19:59 EDT
Volume:40.73M
Turnover:178.49M
Market Cap:2.28B
PE:-4.18
High:4.60
Open:4.51
Low:4.23
Close:4.63
52wk High:7.18
52wk Low:2.77
Shares:535.00M
Float Shares:522.33M
Volume Ratio:0.98
T/O Rate:7.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0219
EPS(LYR):-1.4410
ROE:-56.58%
ROA:-27.33%
PB:2.50
PE(LYR):-2.96

Loading ...

Recursion Director Robert Hershberg Sells 25,000 Common Shares for $125,000

Reuters
·
5 hours ago

Top Recursion Pharma Insider Makes a Major Move With His Shares

TIPRANKS
·
2 hours ago

Cathie Wood’s ARK Investment buys 1.9M shares of Recursion Pharmaceuticals today

TIPRANKS
·
3 hours ago

Movement Alert|Recursion Pharmaceuticals, Inc. Falls 8.21% in Regular Trading, Tempus Data License Amendment Spurs Market Divergence

Market Focus
·
10 hours ago

Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals today

TIPRANKS
·
Oct 06

NASD Most Active Issues

Dow Jones
·
Oct 06

Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)?

Simply Wall St.
·
Oct 03

One Weekend, Thousands Of Compounds: Inside Microsoft's New AI Biology Model

AI Industry Frontlines
·
Oct 03

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

From Exoskeletons to AI: ChronoScale's Billion-Dollar Pivot

Tech News Roundup
·
Oct 02

Recursion Licenses TxFM RNA Foundation Model to Tempus AI for Oncology Use in USD 12 Million Deal

Reuters
·
Sep 22

Tempus Extends Data Licensing Partnership with Recursion Through November 2029

Reuters
·
Sep 22

Tempus AI, Recursion Extend Data License, Amend Fee Structure

MT Newswires Live
·
Sep 21

Recursion, Tempus Expand AI and RNA Collaboration Agreements

TIPRANKS
·
Sep 21

Tempus AI, Recursion extend data license agreement, enter new license agreement

TIPRANKS
·
Sep 21

Tempus AI, - Recursion Grants Tempus Non-Exclusive Worldwide License to Rna Sequencing Model Txfm

THOMSON REUTERS
·
Sep 21

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s Rna Foundation Model

THOMSON REUTERS
·
Sep 21

Tempus AI, -Co and Recursion Extend Data Partnership Through November 2029

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Enters Amendment to Master Agreement with Tempus on Sept 15, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Eliminates Co's Right to Terminate Agreement for Convenience - SEC Filing

THOMSON REUTERS
·
Sep 21